The rising interest in potent weight management has spurred considerable research into novel treatments. Currently, Retatrutide, a dual -action glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist , has shown positive results in patient trials, implying potential for considerable weight loss . Consequently , several individ